The ROE as of November 2024 (TTM) for Cyclerion Therapeutics, Inc. (CYCN) is 28.07%

According to Cyclerion Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is 28.07%. This represents a change of 752.12% compared to the average of 3.29% of the last 4 quarters.

Cyclerion Therapeutics, Inc. (CYCN) Historical ROE (quarterly & annually)

How has CYCN ROE performed in the past?

The mean historical ROE of Cyclerion Therapeutics, Inc. over the last ten years is 155.21%. The current 28.07% ROE has changed -81.92% with respect to the historical average. Over the past ten years (40 quarters), CYCN's ROE was at its highest in in the March 2019 quarter at 482.21%. The ROE was at its lowest in in the March 2023 quarter at -172.69%.

Cyclerion Therapeutics, Inc. (CYCN) ROE by Quarter and Year

Discovering the peaks and valleys of Cyclerion Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Cyclerion Therapeutics, Inc. (CYCN) Average ROE

How has CYCN ROE performed in the past?

The current ROE of Cyclerion Therapeutics, Inc. (CYCN) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Cyclerion Therapeutics, Inc. (CYCN) ROE vs. Peers

How is CYCN’s ROE compared to its peers?

Cyclerion Therapeutics, Inc.’s ROE is greater than Kronos Bio, Inc. (-68.82%), greater than Larimar Therapeutics, Inc. (-35.87%), less than Addex Therapeutics Ltd (105.53%), greater than Achilles Therapeutics plc (-47.36%), greater than Lipella Pharmaceuticals Inc. (-39095.64%), greater than Senti Biosciences, Inc. (-91.09%), greater than Fennec Pharmaceuticals Inc. (-52.10%), greater than Monopar Therapeutics Inc. (-110.60%), greater than Applied Molecular Transport Inc. (-218.56%), greater than Cardio Diagnostics Holdings, Inc. (-308.99%), greater than Sigilon Therapeutics, Inc. (-81.98%), greater than Sonnet BioTherapeutics Holdings, Inc. (-398.33%), greater than ZyVersa Therapeutics, Inc. (-172.51%), less than X4 Pharmaceuticals, Inc. (32.93%), greater than Axcella Health Inc. (-3582.11%), greater than Magenta Therapeutics, Inc. (-61.71%), greater than Kezar Life Sciences, Inc. (-54.50%), less than ContraFect Corporation (403.13%), less than ZIVO Bioscience, Inc. (673.84%), greater than Theseus Pharmaceuticals, Inc. (-24.51%), greater than Erasca, Inc. (-131.94%), greater than Forte Biosciences, Inc. (-117.85%),

Build a custom stock screener for Cyclerion Therapeutics, Inc. (CYCN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cyclerion Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cyclerion Therapeutics, Inc. (CYCN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cyclerion Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.